Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07176416 · ClinicalTrials.gov registry record

Effective Phaco Time and Endothelial Cell Loss When Using Veritas

A clinical trial of Cataract, sponsored by Aloha Vision Consultants.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT07176416 is a study of Cataract that is actively recruiting participants, run by Aloha Vision Consultants. The registered enrollment target is 50 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07176416, a study of Cataract, is actively recruiting participants, sponsored by Aloha Vision Consultants.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.

Conditions Studied

Interventions

  • DEVICE Veritas Vision System

Study Locations (1)

Hawaii

  • Aloha Vision Consultants - ‘Aiea

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-10-03
Est. Completion 2026-10-01

Sponsor

Aloha Vision Consultants

1 total trials

What the Registry Record Tells You About NCT07176416

The ClinicalTrials.gov registry entry for NCT07176416 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (78% lower). The listed sponsor is Aloha Vision Consultants, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Veritas Vision System is the first listed.

NCT07176416 reports 1 study location spanning 1 distinct geographic area - top geographies include Hawaii.

Frequently Asked Questions

What is clinical trial NCT07176416 about?

NCT07176416 is a clinical study titled "Effective Phaco Time and Endothelial Cell Loss When Using Veritas". This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thi...

What is the current status of trial NCT07176416?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-10-03. Estimated completion is 2026-10-01.

What conditions does trial NCT07176416 study?

This clinical trial studies the following conditions: Cataract.

What interventions are being tested in trial NCT07176416?

The interventions under investigation include: Veritas Vision System (DEVICE).

Who is sponsoring clinical trial NCT07176416?

This trial is sponsored by Aloha Vision Consultants, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07176416 being conducted?

This trial has 1 study location across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.